Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 1, FIRST-IN-HUMAN TRIAL OF IM-3050, AN INVESTIGATIONAL FAP-TARGETED RADIOLIGAND THERAPY BEING EVALUATED IN PATIENTS WITH FAP-EXPRESSING ADVANCED SOLID TUMORS.FAP IS A HIGH-POTENTIAL TARGET WITH EXPRESSION IN 75% OF SOLID TUMORS, SAID BOB LECHLEIDER, M.D., CHI.

IMMUNOME ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL EVALUATING IM-3050, AN FAP-TARGETED RADIOLIGAND THERAPY, IN PATIENTS WITH FAP-EXPRESSING ADVANCED SOLID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THE U.S. FOOD AND DRUG ADMINISTRATION (FDA OR THE AGENCY) HAS ACCEPTED ITS NEW DRUG APPLICATION (NDA) FOR VAREGACESTAT, AN INVESTIGATIONAL, ORAL, ONCE-DAILY GAMMA SECRETASE INHIBITOR (GSI), FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS. THE FDA ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION.

IMMUNOME ANNOUNCES U.S. FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR VAREGACESTAT FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JULY 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 344,000 SHARES OF COMMON STOCK TO SEVENTEEN NEW EMPLOYEES UNDER THE COMPANY'S 2024 IN.

IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN DOSED IN THE PHASE 1, FIRST-IN-HUMAN TRIAL OF IM-1617, A POTENTIAL FIRST-IN-CLASS ADC DIRECTED AT AN UNDISCLOSED SOLID TUMOR TARGET AND INCORPORATING HC74, IMMUNOME'S PROPRIETARY TOP1 INHIBITOR PAYLOAD. THE FIRST PATIENT DOSED WITH IM-1617 IS A SIGNIFICANT MILESTONE FOR IMMUNOM.

IMMUNOME ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL EVALUATING IM-1617, A POTENTIAL FIRST-IN-CLASS ADC, IN PATIENTS WITH ADVANCED SOLID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON JUNE 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 353,000 SHARES OF COMMON STOCK TO TWENTY NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUC.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED DETAILED EFFICACY AND SAFETY RESULTS FROM RINGSIDE, THE GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF VAREGACESTAT IN PATIENTS WITH PROGRESSING DESMOID TUMORS. THE DATA ARE BEING PRESENTED TODAY IN AN ORAL ABSTRACT SESSION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL.

IMMUNOME ANNOUNCES DETAILED PHASE 3 RINGSIDE DATA FOR VAREGACESTAT IN ADULTS WITH PROGRESSING DESMOID TUMORS AT THE 2026 ASCO ANNUAL MEETING

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT MEMBERS OF IMMUNOME'S MANAGEMENT WILL PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON JUNE 9, 2026, AT 10:40 A.M. EDT. INTERESTED PARTIES CAN ACCESS THE LIVE AUDIO WEBCAST FOR THIS CONFERENCE FROM THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT WWW.IMMUNOME.COM. THE WEBCA.

IMMUNOME TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE. THIS QUARTER REFLECTS THE PROGRESS WE ARE MAKING IN BUILDING IMMUNOME INTO A MULTI-PROGRAM TARGETED ONCOLOGY COMPANY, SAID CLAY B. SIEGALL, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IMMUNOME. THE NDA SUBMISSION FOR V.

IMMUNOME REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON MAY 1, 2026, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 450,000 SHARES OF COMMON STOCK TO NINETEEN NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDU.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THE SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR VAREGACESTAT, AN INVESTIGATIONAL, ORAL, ONCE-DAILY GAMMA SECRETASE INHIBITOR (GSI), FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS. THE VAREGACESTAT NDA SUBMISSION MARKS AN IMPORTANT MILESTONE FOR IMMUNOME. IT R.

Immunome, Inc.

IMNM

Price

Financial Reports

No items found.

Press Releases

Immunome, Inc.

IMNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

IMNM